Medicine turned cough in the protector of the brain? Ambrocol may slow down the dementia in Parkinson

Researchers at the Lawson Institute of Research (Lawson) fulfill the research arm at St. Joseph Healthcare in London, whether Ambrocol – coughing is safely used for decades in Europe – can slow dementia in people with Parkinson’s disease.

Posted on June 30 in the prestigious The nerve groupThis 12 -month clinical experiment, which included 55 participants with dementia, Parkinson’s disease (PDD) monitoring memory, psychological symptoms and GFAP, which is a blood mark associated with brain damage. Dementia causes Parkinson’s disease memory, confusion, hallucinations and mood changes. About half of those with dementia develops in Parkinson’s within 10 years, which deeply affects patients, families and a health care system.

Under the cognitive neurologist Dr. Stephen Pasterak, the study gave one group of Ambrocol daily while the other group received fake. “Our goal was to change the path of dementia in Parkinson.” Pasternak says. “This early experience provides hope and provides a strong basis for the greatest studies.”

The main results of the clinical experience include:

• Embroxol was safe and treatment well and reached therapeutic levels in the brain
• Psychological symptoms have worsened in the place of imaginary medicine, but they remained stable in those who take an amberroxol.
• Participants with high -risk genetic variables showed improved cognitive performance on Emproxol
• The brain cell damage (GFAP) has increased in the places of imaginary medicine but remained stable with ampirocol, indicating possible protection in the brain.

Although Ambroxol was approved in Europe to treat respiratory conditions and has a long-term safety record-including use in high doses and during pregnancy-it was not approved for any use in Canada or the United States

“The current treatments for Parkinson’s disease and dementia take symptoms but do not stop the basic disease,” explains Pasternak. “These results indicate that Ambroxol may protect the brain function, especially in genetically exhibitions. It provides a promising new treatment path where there are a few of them currently.”

Ambroxol supports a major enzyme called Glucocerebrosidase (GASE), which is produced by GBA1 gene. In people with Parkinson’s disease, GCASE levels are often low. When this enzyme does not work properly, the waste accumulates in the brain cells, which leads to damage. Pasternak learned about Ambroxol during a fellowship at the Sickkids Hospital in Toronto, where it was identified as a treatment for Gaucher – a rare genetic disorder in children caused by GCAS deficiency.

It now applies this research to explore whether GCASE’s strengthening with Ambroxol can help protect the brain in its associated Parkinson’s diseases. “This research is vital because the dementia in Parkinson’s deeply affects patients and families,” Pasternak says. “If a drug like Ambrocol can help, it may provide real hope and improve lives.”

This study, funded by the Weston Foundation, is an important step towards developing new treatments for Parkinson’s and other cognitive disorders, including dementia with Leii bodies. Pasternak and his team are planning to start a clinical experience that is particularly focused on perception later this year.